{"id":"NCT04195698","sponsor":"AbbVie","briefTitle":"Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis","officialTitle":"A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-15","primaryCompletion":"2023-09-11","completion":"2023-09-11","firstPosted":"2019-12-12","resultsPosted":"2025-01-09","lastUpdate":"2025-01-09"},"enrollment":475,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","RINVOQ"]}],"arms":[{"label":"Upadacitinib","type":"EXPERIMENTAL"}],"summary":"This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed.\n\nMain objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events","timeFrame":"UPA/UPA arm: BL visit in Lead-In M16-046 to last dose in Long-Term Extension M19-850 (median time on follow-up is 536 days); DUPI/UPA arm: BL visit in Long-Term Extension M19-850 to last dose plus a 30-day follow-up (median time on follow-up is 399 days).","effectByArm":[{"arm":"DUPI 300mg to UPA 30mg","deltaMin":205,"sd":null},{"arm":"UPA 30mg to UPA 30mg","deltaMin":223,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":116,"countries":["United States","Australia","Canada","Croatia","Czechia","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Malaysia","Netherlands","New Zealand","Norway","Poland","Singapore","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":236},"commonTop":["ACNE","DERMATITIS ATOPIC","BLOOD CREATINE PHOSPHOKINASE INCREASED","COVID-19","HERPES ZOSTER"]}}